The latest: Giant Biogene Holding Co. Ltd. (2367.HK), a fast-growing skin-care products maker, made its trading debut in Hong Kong on Friday with an opening price of HK$26, up 7% from its IPO price of HK$24.30.

Looking up: The local portion of the company’s offering was subscribed by 5,450 investors for a total of 4.71 million shares, representing an oversubscription rate of approximately 1.08 times.

Take Note: The stock priced at the bottom of its IPO range of HK$24.30 to HK$27.70. The deal raised about HK$496 million ($63.6 million), far below the company’s rumored target of HK$3.9 billion.

Digging Deeper: As the largest collagen skin care products manufacturer in China, Giant Biogene’s business has grown rapidly in recent years, with revenue surging from 957 million yuan ($131 million) in 2019 to 1.55 billion yuan last year. Its net profit increased from 575 million yuan to 828 million yuan during the period. The company’s gross margin has exceeded 83% for the past three years, reflecting the high profitability of its business. The company first applied for a Hong Kong listing in May this year, making it the first in the collagen field to go public in China.

Market Reaction: Giant Biogene extended its gains after the strong opening on Friday, finishing up 18.1% at HK$28.70 by the midday break.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…